The DOI matches its Crossref record; 170 of the 170 references it cites were found in a registry or an index; 119 of the 173 sources its claims cite were checked for support.
The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease
Open accessAbstract
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease (NAFLD), is the most common chronic liver disease in the world. The disease progresses from steatosis to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and hepatocellular carcinoma. The modern concept of "multiple parallel hits" interprets disease progression as the result of the synergistic action of lipotoxicity, oxidative stress, mitochondrial dysfunction, endoplasmic reticulum stress, proinflammatory signals, and gut-liver axis dysfunction. Against the background of the limited translation of preclinical data from animal models due to interspecies differences, the importance of human-oriented in vitro platforms compatible with controlled design and high-throughput screening is increasing. The current review analyzes MASLD models based on the HepG2 cell line, systematizing steatosis induction protocols, evaluating the metabolic characteristics and limitations of this cell, and comparing 2D monocultures, 3D systems, and co-cultures. HepG2 has been shown to demonstrate a predictable steatogenic response to free fatty acids (FFAs) and is convenient for reproducing early stages of pathogenesis and primary pharmacological selection of compounds. At the same time, key limitations of the model are highlighted, namely tumor origin, glycolytic shift (Warburg effect), reduced β-oxidation, impaired very-low-density lipoprotein (VLDL) assembly and secretion, and sharply reduced cytochrome P450 (CYP450) activity, as well as limited reproducibility of fructose-induced de novo lipogenesis (DNL). Comparative analysis demonstrates an increase in physiological relevance with the transition from 2D to 3D and multicomponent co-cultures, accompanied by increased complexity and cost, but allowing for the modeling of inflammation and fibrogenesis. The review justifies approaches to selecting the appropriate platform based on the specific research task.
Overview
CoChat Summary
## TL;DR
This narrative review argues that HepG2 is a useful but incomplete human in vitro model for MASLD, especially for early hepatocyte-centric events like steatosis, lipotoxicity, ER stress, oxidative stress, and mitochondrial dysfunction. It concludes that model choice should match the research question, with 2D HepG2 best for rapid screening and 3D/co-culture systems better for inflammation, fibrogenesis, and higher physiological relevance.
## Key findings
- HepG2 shows a predictable steatogenic response to free fatty acids and is widely used for MASLD/NAFLD modeling; the review says 2D monocultures are the most accessible tool for early cell damage and can reproduce lipid accumulation, lipotoxicity, ER stress, oxidative stress, and mitochondrial dysfunction.
- For 2D HepG2 models, the review identifies OA:PA in a 2:1 ratio at 0.5–1.0 mM for 24 h as the preferred setup for screening anti-steatotic effects, because it balances steatogenesis and viability.
- In one cited study, a 2:1 OA/PA ratio at 2 mM induced significant lipid accumulation with minimal toxicity, while palmitate alone caused pronounced cytotoxic and apoptotic responses; another cited triculture model using FFAs + glucose + insulin + LPS + TGF-β + BSA reproduced steatosis, oxidative stress, inflammation, and fibrogenesis.
- The review states that physiological relevance increases from 2D monocultures to 3D models to multicomponent co-cultures, but complexity and cost also rise; 3D organ-on-a-chip platforms are highlighted for simultaneously assessing therapeutic efficacy and toxicity.
## Methods
- Narrative review of MASLD models based on the HepG2 cell line.
- The paper synthesizes published experimental protocols and compares modeling approaches across 2D monocultures, 3D systems, and co-cultures/tricultures.
- Main analysis focuses on steatosis induction conditions, metabolic characteristics and limitations of HepG2, and the physiological relevance of different model formats.
## Limitations
- Stated in the paper: HepG2 has tumor origin, a glycolytic shift (Warburg effect), reduced β-oxidation, impaired VLDL assembly/secretion, sharply reduced CYP450 activity, and limited reproducibility for fructose-induced de novo lipogenesis.
- Stated in the paper: 2D HepG2 monocultures lack non-parenchymal liver cells and non-physiological geometry, while 3D models are harder to standardize and can limit access for post-experimental analysis.
- Evident from the text: this is a narrative review rather than a new experimental study, so its conclusions depend on heterogeneous published studies with differing FFA compositions, exposure times, and readouts.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
65 Valid · 4 Not valid · 11 Not checked · 40 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The major human isoenzymes of drug metabolism (CYP3A4, CYP2D6, CYP2C9, CYP2C19, and CYP1A2) lack direct orthologs in mice.”
§ The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease > 2. Advantages of MASLD Models on Cell Lines Compared to Animals > 2.1. Species-Specific Differences in Metabolism
What the sources say
- Disputedcites [53] Hammer, 2021, Cross-Species Analysis of Hepatic Cytochrome P450 and Transport Protein Expression, Arch. Toxicol. sourceExperimental — accuracy not yet measured
Results, Table 1 is titled “Selected orthologous CYP proteins in human, rat and mouse” and lists mouse counterparts for CYP1A2, CYP2D6, CYP2C9, and CYP2C19. Its mouse entry for CYP3A4 is blank, so the paper does not support the claim that all five lack direct mouse orthologs. Page numbers were not supplied in our copy. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
- Not checked yetcites [54] Martignoni, 2006, Comparison of Mouse and Rat Cytochrome P450-Mediated Metabolism in Liver and Intestine, Drug Metab. Dispos. Biol. Fate Chem. source
Checked before — its earlier verdict is held back until a new check runs.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“The range of 0.1 to 2.0 mM for the combination of FAs is the standard range for modeling MASLD in 2D HepG2 monoculture [93,100,125,126,127,128].”
§ The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease > 3. Human Liver Cell Lines for Modeling NAFLD > 3.3. Analysis of MASLD Models in HepG2 Cells
What the sources say
- Not checked yetcites [93] Cui, 2010, Quantification and Mechanisms of Oleic Acid-Induced Steatosis in HepG2 Cells, Am. J. Transl. Res.
- Not matchedcites [100] 2015, In Vitro Treatment of HepG2 Cells with Saturated Fatty Acids Reproduces Mitochondrial Dysfunction Found in Nonalcoholic Steatohepatitis, Dis. Model. Mech.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Disputedcites [125] Arruda, V.M., Azevedo, G.T., Granato, M.J.M.G., Matos, A.C.P., Araújo, T.G., and Guerra, J.F.d.C. (2024). Oxidative Stress and Annexin A2 Differential Expression in Free Fatty Acids-Induced Non-Alcoholic Fatty Liver Disease in HepG2 Cells. Int. J. Mol. Sci., 25. sourceExperimental — accuracy not yet measured
The Introduction says there is little consensus on experimental standardization, contrary to calling 0.1–2.0 mM a standard range. The Discussion instead describes concentrations of 0.3–3 mM in most in vitro studies. Although this paper uses combined fatty acids at 1 and 2 mM in HepG2 cells (Materials and Methods, §4.3), it does not establish the claimed range as standard. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [126] Donato, 2007, A Human Hepatocellular in Vitro Model to Investigate Steatosis, Chem. Biol. Interact. source
- Not checked — no full text of the sourcecites [127] Torabi, 2025, Investigating the Process of Apoptosis in HepG2 Cells Treated with Palmitate, Oleate, and Palmitate/Oleate Combination, Arab J. Gastroenterol. source
- Not checked — no full text of the sourcecites [128] Bao, Q., Zhang, X., Chen, Y., Wang, T., and Siqin, B. (2024). In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease. J. Vis. Exp. JoVE. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Along with this, the HepG2 cell line shows functional weakening of mitochondrial β-oxidation of fatty acids.”
§ The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease > 3. Human Liver Cell Lines for Modeling NAFLD > 3.2. Metabolic Profile, Advantages, and Limitations of the HepG2 Cell Line for Modeling MASLD
What the sources say
- Not matchedcites [100] 2015, In Vitro Treatment of HepG2 Cells with Saturated Fatty Acids Reproduces Mitochondrial Dysfunction Found in Nonalcoholic Steatohepatitis, Dis. Model. Mech.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Partly supportedcites [101] Suzuki, 2023, CLPX Regulates Mitochondrial Fatty Acid β-Oxidation in Liver Cells, J. Biol. Chem. sourceExperimental — accuracy not yet measured
The Results section, “Knockout of CLPX induces β-oxidation in HepG2 cells” (page unavailable), reports that untreated HepG2 cells with CLPX had lower mitochondrial β-oxidation activity than CLPX-knockout HepG2 cells. This supports reduced activity under that specific comparison, but not a general claim that the HepG2 cell line has functionally weakened β-oxidation. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In contrast, in vitro models express human apolipoproteins, lipoprotein receptors, and lipid transport proteins [43,44,45,46], providing a metabolically relevant context for studying lipid accumulation pathways relevant to MASLD.”
§ The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease > 2. Advantages of MASLD Models on Cell Lines Compared to Animals > 2.1. Species-Specific Differences in Metabolism
What the sources say
- Partly supportedcites [43] Kiss, I., Neuwert, N., Oberle, R., Hengstschläger, M., Osmanagic-Myers, S., and Stangl, H. (2025). Hepatic Lipoprotein Metabolism: Current and Future In Vitro Cell-Based Systems. Biomolecules, 15. sourceExperimental — accuracy not yet measured
Section 4.5 reports that liver organoids express several apolipoproteins and have lipoprotein receptors, and proposes using them to study lipid-droplet formation and MAFLD progression. The paper discusses lipid transport proteins, but the cited passages do not establish their expression in these in vitro models; that part of the attributed claim remains unsupported. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [44] Ramli, 2020, Human Pluripotent Stem Cell-Derived Organoids as Models of Liver Disease, Gastroenterology source
- Not matchedcites [45] Moon, 2016, Complex Effects of Inhibiting Hepatic Apolipoprotein B100 Synthesis in Humans, Sci. Transl. Med.
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Partly supportedcites [46] Pollard, 2016, High-Density Lipoprotein Biogenesis: Defining the Domains Involved in Human Apolipoprotein A-I Lipidation, Biochemistry sourceExperimental — accuracy not yet measured
The Materials and Methods section ('Cell Culture and Purification of Nascent HDL'; page unavailable) describes an in vitro model using HEK293 cells expressing the lipid transporter ABCA1, incubated with human apoA-I. The paper does not show those cells expressing apolipoproteins or lipoprotein receptors, and it studies HDL formation rather than lipid accumulation pathways in MASLD. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Against the background of the limited translation of preclinical data from animal models due to interspecies differences, the importance of human-oriented in vitro platforms compatible with controlled design and high-throughput screening is increasing.”
- Also stated in: § 1. Introduction · plain
“Animal models have provided valuable insights into the disease, but interspecies differences in liver metabolism, genetics, and disease progression limit the transferability of results [26,27].”
§ The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease > Abstract
What the sources say
- Supportedcites [26] Soret, P.-A., Magusto, J., Housset, C., and Gautheron, J. (2021). In Vitro and In Vivo Models of Non-Alcoholic Fatty Liver Disease: A Critical Appraisal. J. Clin. Med., 10. source
The Conclusions (page unavailable) describe disappointing translation of preclinical findings to humans, identify interspecies differences as a challenge, and discuss advances in in vitro models. Section 3.3 (page unavailable) says organoids can support high-throughput screening and that chip models are more reproducible because of standardized protocols, supporting the claim about human-oriented platforms and controlled design. (LLM, conf=0.88)
- Partly supportedcites [27] Wang, S.-X., Yan, J.-S., and Chan, Y.-S. (2022). Advancements in MAFLD Modeling with Human Cell and Organoid Models. Int. J. Mol. Sci., 23. sourceExperimental — accuracy not yet measured
Section 1.4 says species-specific differences may hinder translation from animal MAFLD models and calls human in vitro models critical. The Concluding Remarks identify high-throughput drug screening as an application, while Section 4.1 describes precise control of microfluidic models but says their low throughput makes high-throughput screening challenging. The claim therefore overgeneralizes the combination of controlled design and high-throughput compatibility. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 1. Introduction · plain
34 more claims · 17 with their cited sources checked
Create a free account to see all 120 claims and to verify the 14 references still open.
- It may state two separate claims as one. 78
- Probably not a substantial claim. 14
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
The Principles of Humane Experimental Technique
(1960) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1960.tb73127.x · Cited by 4,912
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
Younossi, Z. M., Golabi, P., Paik, J. M., Henry, A., Van Dongen, C., & Henry, L. (2023) · Hepatology · doi:10.1097/hep.0000000000000004 · Cited by 3,383
The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis
Riazi, K., Azhari, H., Charette, J. H., Underwood, F. E., King, J. A., Afshar, E. E., Swain, M. G., Congly, S. E., Kaplan, G. G., & Shaheen, A.-A. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00165-0 · Cited by 2,246
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280
Triglyceride Metabolism in the Liver
Alves‐Bezerra, M., & Cohen, D. E. (2017) · Comprehensive Physiology · doi:10.1002/cphy.c170012 · Cited by 1,016
Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review
Chan, W.-K., Chuah, K.-H., Rajaram, R. B., Lim, L.-L., Ratnasingam, J., & Vethakkan, S. R. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes23052 · Cited by 776
Cited by
Котлярова, А. А., & Kotlyarov, S. N. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104453 · Cited by 1
Self-citationDistinct OA:PA Ratios Generate Discrete Hepatocellular Phenotypes in HepG2 Cells
Jeong, H. Y., Han, Y., Park, J., Noh, H., Moon, E., & Huh, Y. (2026) · Cells · doi:10.3390/cells15191774
Kavak, E., Çetin, D., Konuş, M., & Kıvrak, A. (2026) · ACS Omega · doi:10.1021/acsomega.6c04482
Feguro, K. F., Fauzi, N. M., Husain, K., Mustafa, S. H., & Jasamai, M. (2026) · Molecules · doi:10.3390/molecules31152708
Xiao, Z., Bian, H., & Huang, Y. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.154435
Metadata
- Authors
- Kotlyarova, A., Iskrina, A., & Kotlyarov, S.
- Affiliations
- Department of Pharmacy Management and Economics, Ryazan State Medical University, 390026 Ryazan, Russia
- Ryazan State Medical University named after Academician I.P. Pavlov (RU)
- Corresponding author
- Kotlyarov, Stanislav
- Venue
- International journal of molecular sciences
- Publisher
- MDPI AG
- Published
- 2026-04-10
- Volume
- 27
- Issue
- 8
- Pages
- 3399
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC13116571
- OpenAlex
- W7153190438
- Cited by
- 10
- References
- 156
- Citations by year
- 2026: 10
- FWCI
- 7.39
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Funders
- Russian Science Foundation (25-25-01166)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- HepG2 cells, non-alcoholic fatty liver disease, steatosis, 3D cell culture, co-culture model, free fatty acids, de novo lipogenesis, Warburg effect, mitochondrial dysfunction, oxidative stress, endoplasmic reticulum stress, lipotoxicity, VLDL secretion, cytochrome P450, hepatocellular carcinoma, fibrosis, inflammation, high-throughput screening
- MeSH terms
- Animals, Fatty Liver, Humans, Models, Biological, Hep G2 Cells, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease. https://app.cochat.ai/papers/10.3390/ijms27083399
- The paper
- Kotlyarova, A., Iskrina, A., & Kotlyarov, S. (2026). The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease. International journal of molecular sciences. https://doi.org/10.3390/ijms27083399
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.